Physician profile
Kevin Jonathan Donohue
NPI 1366604555
$654,741.20
in general payments reported to CMS, 2019-2025
56 companies · $106K in 2025
The $106K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106K · 2020: $101K · 2021: $76K · 2022: $86K · 2023: $91K · 2024: $88K · 2025: $106K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $251K · Travel and Lodging: $18K · Food and Beverage: $13K · Consulting Fee: $2,900 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $250,526.50 |
| Travel and Lodging | $18,135.45 |
| Food and Beverage | $12,649.26 |
| Consulting Fee | $2,899.90 |
| Education | $137.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $604,922.20 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14,041.37 | 2019-2025 | Jardiance |
| Ascendis Pharma Endocrinology INC | $13,377.50 | 2023-2025 | Yorvipath |
| Astrazeneca Pharmaceuticals Lp | $5,039.25 | 2019-2023 | Farxiga |
| Senseonics, Incorporated | $4,130.00 | 2022-2025 | Eversense |
| Tolmar, INC. | $3,221.81 | 2023-2025 | Jatenzo |
| Novo Nordisk INC | $1,306.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $1,210.56 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $607.40 | 2021-2025 | Recorlev, Gvoke Hypopen, Keveyis |
| Amneal Pharmaceuticals LLC | $524.58 | 2019-2025 | Unithroid |
| Corcept Therapeutics | $485.85 | 2021-2025 | Korlym |
| Amgen INC. | $412.44 | 2019-2025 | Evenity, Prolia, Tepezza |
| Antares Pharma, INC. | $387.80 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Abbott Laboratories | $376.44 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Tandem Diabetes Care, INC. | $365.20 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $303.53 | 2021-2025 | |
| Dexcom, INC. | $301.63 | 2019-2025 | Dexcom G6 Transmitter |
| Sequel Med Tech, LLC | $291.44 | 2025 | Twiist |
| Astellas Pharma US INC | $251.98 | 2023-2025 | Veozah |
| Mannkind Corporation | $249.94 | 2021-2025 | Afrezza |
| Insulet Corporation | $201.15 | 2021-2024 | Omnipod |
| Horizon Therapeutics Plc | $182.73 | 2020-2023 | Tepezza |
| Medtronic Minimed, INC. | $173.37 | 2019 | |
| Biotissue Holdings INC. | $169.86 | 2025 | |
| Recordati_rare_diseases_inc. | $163.53 | 2022-2025 | Isturisa, Signifor Lar |
| Radius Health, INC. | $162.20 | 2021-2024 | Tymlos |
| Medtronic, INC. | $135.53 | 2021-2025 | Minimed 780g |
| Alexion Pharmaceuticals, INC. | $128.00 | 2022-2025 | Strensiq |
| Amphastar Pharmaceuticals, INC. | $124.26 | 2024-2025 | |
| Beta Bionics, INC. | $120.82 | 2024 | Ilet Bionic Pancreas |
| Pfizer INC. | $119.82 | 2022-2023 | |
| Abbvie INC. | $110.70 | 2021-2025 | |
| Amryt Pharma Holdings Ltd | $108.06 | 2022-2023 | Mycapssa |
| Madrigal Pharmaceuticals | $91.90 | 2025 | Rezdiffra |
| Zealand Pharma US, INC. | $80.62 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $76.31 | 2021-2023 | |
| Ascensia Diabetes Care US INC. | $72.61 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $72.02 | 2023-2024 | |
| Nevro Corp. | $67.95 | 2022 | |
| Kyowa Kirin, INC. | $63.61 | 2025 | |
| Embecta Corp. | $59.25 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Ibsa Pharma INC. | $58.63 | 2019-2024 | Tirosint, Licart |
| Azurity Pharmaceuticals, INC. | $49.62 | 2023-2025 | Adthyza, Azmiro |
| Halozyme INC | $47.65 | 2023 | |
| Amarin Pharma, INC. | $38.50 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $36.86 | 2019 | |
| Shire North American Group INC | $34.98 | 2019 | |
| Globus Medical, INC. | $34.04 | 2025 | Senza |
| Becton, Dickinson and Company | $31.02 | 2022 | |
| Vivus LLC | $26.33 | 2019 | |
| Eusa Pharma (US) LLC | $20.92 | 2022 | |
| Neurocrine Biosciences, INC. | $19.27 | 2025 | |
| Cequr Corporation | $16.21 | 2025 | Cequr Simplicity |
| Acella Pharmaceuticals, LLC | $13.77 | 2023 | NP Thyroid 60 |
| Eisai INC. | $11.90 | 2019 | |
| Clarus Therapeutics INC. | $9.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Donohue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.